Astellas has identified neuroscience as a key focus for research and development
because of the high unmet needs and tremendous research potential in this therapeutic
area. We are committed to neuroscience so that we can continue to make a significant
and positive difference in the lives of patients. Our efforts in neuroscience straddle
both central nervous system disorders and pain therapeutics.
The Central Nervous System Therapeutic Area focuses on treatments in neurology and
psychiatry. These diseases and disorders include a wide variety of unrelated conditions
with differing origins, such as Alzheimer's disease, multiple sclerosis, schizophrenia
and bipolar disorder. All of these diseases have serious consequences for the quality
of life of millions of patients and their families.
As a global company committed to improving the lives of people around the world
with innovative and effective medicines, Astellas is joining the global effort to
ease the burden of Alzheimer's disease. "Alzheimer's disease is a devastating condition,"
notes Dr. Mark Weinberg, global head of Astellas' Central Nervous System Therapeutic
Area. "Astellas is working to change tomorrow for the patients and families that
suffer with Alzheimer's disease. We are developing some treatments that will improve
the symptoms of patients and others that will slow the course or delay the onset
of the disease."
Schizophrenia is a similarly destructive condition for patients and their loved
ones. Astellas is exploring ways to treat the symptoms of psychosis and cognitive
impairment that burden schizophrenic patients. In addition, we are trying to understand
more fully the genetic basis of schizophrenia and other psychiatric conditions,
which will ultimately lead to new targets and treatments.
The Pain Therapeutic Area is exploring treatments that affect peripheral sensitization,
central sensitization and central disinhibition. These therapies will treat many
chronic pain conditions, including neuropathic pain, osteoarthritis, chronic back
pain, and fibromyalgia. As in other therapeutic areas, we will apply our precision
medicine approach to differentiate our products and enhance the likelihood of their
In all of the key therapeutic areas in which we focus, Astellas aspires to become
a leading company in the development of precision medicine. We are moving away from
the traditional approach of "one size fits all" (mass medicine) toward "the right
drug for the right patient" (precision medicine). Precision medicine means to offer
highly effective therapeutic options for precisely defined patient populations based
on molecular targeting and precise diagnostics.
To learn more about the progress of Astellas' clinical development projects, visit
of R&D Pipeline" on the Astellas Pharma Inc. Web site.